Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2012
05/31/2012US20120135082 Extended release compositions comprising as active compound venlafaxine hydrochloride
05/31/2012US20120135079 Modified Release Tranexamic Acid Formulation
05/31/2012US20120135078 Angina treatment
05/31/2012US20120135075 Dosage form
05/31/2012US20120135074 High-Strength Testosterone Undecanoate Compositions
05/31/2012US20120135073 Oral Drug Delivery System
05/31/2012US20120135072 Oral Drug Delivery System
05/31/2012US20120135071 Abuse-proofed dosage form
05/31/2012US20120135069 Nanonized testosteron formulations for improved bioavailability
05/31/2012US20120135066 Regulators of the hedgehog pathway, compositions and uses related thereto
05/31/2012US20120135065 Amphoteric Liposomes, A Method Of Formulating An Amphoteric Liposome And A Method Of Loading An Amphoteric Liposome
05/31/2012US20120135063 Glucuronic acid-containing glucan, process for production of same, and use of same
05/31/2012US20120135062 Wound dressing materials
05/31/2012US20120135055 Dry Powder Inhaler Formulations
05/31/2012US20120135054 Poly (Ester Ether Amide)s and Uses Thereof
05/31/2012US20120135053 Nanoparticulate telmisartan compositions and process for the preparation thereof
05/31/2012US20120135050 Extended-release formulation for reducing the frequency of urination and method of use thereof
05/31/2012US20120135048 novel formulation of indomethacin
05/31/2012US20120135047 Novel formulation of diclofenac
05/31/2012US20120135046 Corticosteroid particles and method of production
05/31/2012US20120135042 Methods Using Immunomodulatory Compounds For Treatment of Certain Leukemias
05/31/2012US20120135041 Immunosuppressor based on the blockage of tcr-nck interaction
05/31/2012US20120135031 Method of enhancing an immune response
05/31/2012US20120135013 CD45 and Methods and Compounds Related Thereto
05/31/2012US20120135002 Compounds and Methods for the Treatment of Cancer
05/31/2012US20120135000 Methods and compositions for treating ocular disorders
05/31/2012US20120134997 Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
05/31/2012US20120134996 Anti-met monoclonal antibody, fragments and vectors thereof , for the treatment of tumors and corresponding products
05/31/2012US20120134991 Compositions and methods for modulating d1-d2 dopamine receptor interaction and function
05/31/2012US20120134987 Kinase inhibitors and methods of their use
05/31/2012US20120134986 Methods of Prognosis for Non-Hodgkin Lymphoma
05/31/2012US20120134981 Genes linking several complications of type-2 diabetes (t2d)
05/31/2012US20120134979 Methods and compositions for the treatment of sickle cell disease
05/31/2012US20120134977 Prodrugs containing albumin binding probe
05/31/2012US20120134976 Oral formulations for counteracting effects of aging
05/31/2012US20120134966 Embryonic stem cell specific micrornas promote induced pluripotency
05/31/2012US20120134959 Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
05/31/2012US20120134958 Hydroxyethyl starch-containing polypeptide compositions
05/31/2012US20120134955 Pyrimidopyrimidoindazole derivative
05/31/2012US20120134951 Topical Gels and Methods of Using the Same
05/31/2012US20120134950 Adhesion-Promoting thin Film and Moisture Resistant Skin Barrier Compositions
05/31/2012US20120134948 Antimicrobial ether guanidines
05/31/2012US20120134935 Use of mometasone furoate for treating airway passage and lung disease
05/31/2012US20120134934 Glycine derivatives and medicinal compositions thereof
05/31/2012US20120134933 Use of high-doses of monomeric contrast medium containing iodine in x-ray diagnostics, in particular in interventional x-ray diagnostics and in radiation therapy assisted by contrast media containing iodine
05/31/2012US20120134929 Treatment of macrophage-related disorders
05/31/2012US20120134926 Charge-dynamic polymers and delivery of anionic compounds
05/31/2012US20120134925 Application and Uses of PRG4 and Therapeutic Modulation Thereof
05/31/2012US20120134919 Ion substituted calcium phosphate particles
05/31/2012US20120132218 Smokeless tobacco cessation product
05/31/2012US20120132204 Unit dose dry powder inhaler
05/31/2012DE102010052939A1 Ointment-shaped agent, useful e.g. as pain relieving ointment, comprises a carrier substance and many substances comprising heparin, hydroxyethyl salicylate, diclofenac, and essential oil and/or at least a part of the essential oil
05/31/2012DE102010052847A1 Verfahren zur Herstellung einer PPI-haltigen pharmazeutischen Zubereitung A process for the preparation of a pharmaceutical preparation containing PPI-
05/31/2012DE102005023301B4 Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat A pharmaceutical composition comprising progestins and / or estrogens and 5-methyl- (6S) -tetrahydrofolate
05/31/2012CA2856812A1 Carbonic anhydrase inhibitors with antimetastatic activity
05/31/2012CA2856101A1 Immunomodulatory compositions
05/31/2012CA2849207A1 Methods of screening compounds that are cytotoxic to tumor cells and methods of treating tumor cells using such compounds
05/31/2012CA2820618A1 Methods of treatment using selective bcl-2 inhibitors
05/31/2012CA2820600A1 Glycine derivatives and their use as muscarinic receptor antagonists
05/31/2012CA2818898A1 Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and mmanufacture
05/31/2012CA2818889A1 Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
05/31/2012CA2818885A1 Benzoxazepines as inhibitors of mtor and methods of their use and manufacture
05/31/2012CA2818871A1 Integrin-linked kinase inhibitors
05/31/2012CA2818842A1 Diphenyl-amine derivatives: uses, process of synthesis and pharmaceutical compositions
05/31/2012CA2818824A1 Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
05/31/2012CA2818805A1 Novel phosphonic acids as s1p receptor modulators
05/31/2012CA2818701A1 Modulating oncolytic vsv and upregulating rae1 and nup98 with statins
05/31/2012CA2818505A1 Oligosaccharide mixture and food product comprising this mixture, especially infant formula
05/31/2012CA2818249A1 Pharmaceutical compositions
05/31/2012CA2818194A1 Solid dosage forms of oleyl phosphocholine
05/31/2012CA2818100A1 Compounds and their use
05/31/2012CA2818050A1 Bicyclic gpr119 modulators
05/31/2012CA2818015A1 Oligosaccharide mixture and food product comprising this mixture, especially infant formula
05/31/2012CA2818007A1 Multicomponent system of rosuvastatin calcium salt and sorbitol
05/31/2012CA2817629A1 Salts and crystalline forms of an apoptosis-inducing agent
05/31/2012CA2817531A1 Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy
05/31/2012CA2817177A1 Fast disintegrating compositions comprising nabilone and randomly methylated beta cyclodextrin
05/31/2012CA2816395A1 Antifungal 5,6-dihydro-4h-pyrrolo[1,2-a] [1,4]- benzodiazepines and 6h-pyrrolo[1,2-a] [1,4]benzodiazepines substituted with phenyl derivatives
05/31/2012CA2816288A1 Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
05/31/2012CA2815935A1 Intermediate compounds and processes for the preparation of quinoline derivatives such as laquinimod sodium
05/31/2012CA2815390A1 Methods of treating eye diseases associated with inflammation and vascular proliferation
05/31/2012CA2815029A1 Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as jak inhibitors
05/31/2012CA2814231A1 4- (5-cyano-pyrazol-1-yl) -piperidine derivatives as gpr 119 modulators
05/30/2012EP2458006A1 Compounds and methods for modulating expression APOB
05/30/2012EP2458005A1 Fgf21 cis-element binding substance
05/30/2012EP2457923A1 Sterol derivative
05/30/2012EP2457921A2 Aureolic acid derivatives, the method for preparation thereof and the uses thereof
05/30/2012EP2457920A1 Oligosaccharides comprising an aminooxy group and conjugates thereof
05/30/2012EP2457919A1 Oligosaccharides comprising an aminooxy group and conjugates thereof
05/30/2012EP2457918A2 Crystalline solvates and complexes of (1s)-1,5-anhydro-1-c-(3-((phenyl) methyl) phenyl)-d-glucitol derivatives with amino acids as SGLT2 inhibitors for the treatment of diabetes
05/30/2012EP2457913A2 Heteroaryl compounds, compositions thereof, and methods of treatment therewith
05/30/2012EP2457911A1 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha.7-nAChR ligands for the treatment of CNS diseases.
05/30/2012EP2457907A1 Flavagline derivatives as neuroprotective agents
05/30/2012EP2457906A1 Derivatives of 1,2,4-benzothiadiazine dioxide, their preparation and use as allosteric modulators of the AMPA receptor
05/30/2012EP2457903A1 Cannabinoid receptor ligands
05/30/2012EP2457901A1 Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors
05/30/2012EP2457900A1 New pyrazole derivatives having CRTh2 antagonistic behaviour
05/30/2012EP2457897A1 Benzo (f) isoindol-2-ylphenyl acetic acid derivatives as ep4 receptor agonists
05/30/2012EP2457895A1 Tetrapeptide analogs
05/30/2012EP2457585A1 Methods for treating conditions associated with MASP-2 dependent complement activation
1 ... 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 ... 7860